<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040078</url>
  </required_header>
  <id_info>
    <org_study_id>20090601</org_study_id>
    <nct_id>NCT01040078</nct_id>
  </id_info>
  <brief_title>Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centers for Disease Control and Prevention, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to generate data on immunogenicity and safety of the monovalent
      H1N1 vaccine in support of the development and registration.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Influenza</condition>
  <condition>Swine-origin A/H1N1 Influenza</condition>
  <arm_group>
    <arm_group_label>7.5ug H1N1 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>360 subjects to receive two doses 7.5ug H1N1 influenza vaccine on Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15ug H1N1 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>360 subjects to receive two doses 15ug H1N1 influenza vaccine on Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>seasonal influenza vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>180 subjects to receive two doses seasonal influenza vaccine on Day 0 and Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7.5ug H1N1 Influenza vaccine</intervention_name>
    <description>0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21</description>
    <arm_group_label>7.5ug H1N1 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>15ug H1N1 vaccine</intervention_name>
    <description>0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21</description>
    <arm_group_label>15ug H1N1 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>seasonal influenza vaccine</intervention_name>
    <description>0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21</description>
    <arm_group_label>seasonal influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged &gt;= 6 months to =&lt;35 months at the time of the first study
             vaccination. Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5
             kg

          -  Informed consent form has been signed and dated by the parent(s) or other legally
             acceptable representative Subject and parent/legal representative are able to attend
             all scheduled visits and to comply with all trial procedures

        Exclusion Criteria:

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the first trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination

          -  Planned receipt of any vaccine prior to the Day 42 blood sample

          -  Receipt of blood or blood-derived products in the past 3 months which might interfere
             with the assessment of immune response

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2
             consecutive weeks within the past 3 months)

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccine(s) used in the trial or to a vaccine
             containing any of the same substances

          -  Thrombocytopenia contraindicating intramuscular (IM) vaccination as reported by
             parents/legal representative

          -  Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion
             contraindicating IM vaccination

          -  Chronic illness that in the opinion of the Investigator is at a stage where it might
             interfere with trial conduct or completion

          -  Family members of the employees or the Investigator

          -  Previous participation in a trial investigating a vaccine with the swine-origin A/H1N1
             influenza strain

          -  Confirmed infection with the novel influenza A/H1N1 strain

          -  Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection
             on the day of vaccination, according to Investigator judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lingchuan County CDC</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <zip>541000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanping Li, Doctor</last_name>
      <phone>0773 6812175</phone>
      <email>lyp898@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luxi County CDC</name>
      <address>
        <city>Xiangxi Prefecture</city>
        <state>Hunan</state>
        <zip>416100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fangjun Li, Doctor</last_name>
      <phone>0743 4265397</phone>
      <email>fangjunliself678@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yandu District CDC</name>
      <address>
        <city>Yancheng</city>
        <state>Jiangsu</state>
        <zip>224001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuemei Hu, Doctor</last_name>
      <phone>0515 8324084</phone>
      <email>993832717@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2009</study_first_submitted>
  <study_first_submitted_qc>December 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2009</study_first_posted>
  <last_update_submitted>December 29, 2009</last_update_submitted>
  <last_update_submitted_qc>December 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Xiaofeng Liang</name_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

